In glioblastoma animal models, CCR2–CCL2 inhibitors effectively reduced the M2-TAM infiltration at the tumor site, improved survival, and demonstrated a better outcome of combinatorial anti-cancer therapies (11, 209). This evidence concerns the gene CCL2 and cancer.